Luliska Cream contains Luliconazole 1% w/w, an imidazole antifungal agent indicated for the topical treatment of superficial fungal infections such as dermatophytosis, tinea corporis, tinea cruris, and tinea pedis. Luliconazole exerts its antifungal effect by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. The cream formulation allows for targeted application to affected skin areas, promoting rapid relief from symptoms including itching, redness, and scaling. Luliska Cream is typically applied once daily to the affected area and surrounding skin after cleansing and drying, continuing treatment for the duration prescribed by a healthcare professional, usually 2 to 4 weeks depending on the infection type and severity. It is generally well tolerated, with minimal adverse effects; however, mild local reactions such as burning, itching, or irritation may occur. Luliska Cream should not be used in patients with known hypersensitivity to Luliconazole or any cream excipients. Use during pregnancy and lactation should be under medical supervision. Proper adherence to treatment and hygiene measures is essential to prevent recurrence and ensure effective resolution of fungal infections.